ClinicalTrials.gg
CompletedNCT02974361Updated May 3, 2017

Impact of Excipients on Pharmacokinetics of OXPzero(TM) Ibuprofen

A Phase 1 interventional study of Ibuprofen and Ibuprofen Lysine in Pharmacokinetics, sponsored by Oxford Pharmascience Ltd. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-03.

Sponsored by Oxford Pharmascience Ltd · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is to help development of a new version of Ibuprofen, called Ibuprofen-LDH. Ibuprofen-LDH will be used as a treatment for muscular pains, headache, fever etc. This new version of ibuprofen is expected to produce fewer stomach/intestine related side effects when compared to many existing marketed formulations of Ibuprofen.

This study is split into 3 parts. Part A is a 7 way crossover, Part B is a maximum of a 6 way crossover and Part C is a maximum of a 4 way crossover. The size of Parts B \& Part C and allocated interventions will be confirmed after review of data from Parts A and/or B respectively.

A total of 30 subjects will take part in the study; 10 per study part.

The key objective is to assess the pharmacokinetics properties of Ibuprofen-LDH, with and without a selection of different excipients. The pharmacokinetic properties will include how quickly the drug is absorbed into the bloodstream and also the maximum concentration of drug that reaches the bloodstream.

02

Conditions studied

  • Pharmacokinetics
03

In context

Lead sponsor

Oxford Pharmascience Ltd is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subjects
  • 18 - 30 kg/m2
  • Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of significant renal, hepatic, gastrointestinal, central nervous system, respiratory, cardiovascular, or metabolic dysfunction
  • Recent or concurrent use of prescription or non-prescription medications, other than
  • Allergy or sensitivity to NSAIDs
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Part A Ibuprofen control

    Drug: Ibuprofen

  • Experimental
    Part A Ibuprofen-LDH

    Drug: Ibuprofen-LDH

  • Experimental
    Part A Ibuprofen-LDH Excipient Combo 1

    Drug: Ibuprofen-LDH

  • Experimental
    Part A Ibuprofen-LDH Excipient Combo 2

    Drug: Ibuprofen-LDH

  • Experimental
    Part A Ibuprofen-LDH Excipient Combo 3

    Drug: Ibuprofen-LDH

  • Experimental
    Part A Ibuprofen-LDH Excipient Combo 4

    Drug: Ibuprofen-LDH

  • Active comparator
    Part A Ibuprofen Lysine

    Drug: Ibuprofen Lysine

  • Active comparator
    Part B Ibuprofen

    Drug: Ibuprofen

  • Experimental
    Part B Ibuprofen LDH Excipient Combo 1

    Drug: Ibuprofen-LDH

  • Experimental
    Part B Ibuprofen LDH Excipient Combo 2

    Drug: Ibuprofen-LDH

  • Experimental
    Part B Ibuprofen LDH Excipient Combo 3

    Drug: Ibuprofen-LDH

  • Experimental
    Part B Ibuprofen LDH Excipient Combo 4

    Drug: Ibuprofen-LDH

  • Active comparator
    Part C Ibuprofen

    Drug: Ibuprofen

  • Experimental
    Part C Ibuprofen LDH Excipient Combo 1

    Drug: Ibuprofen-LDH

  • Experimental
    Part C Ibuprofen LDH Excipient Combo 2

    Drug: Ibuprofen-LDH

  • Experimental
    Part C Ibuprofen LDH Excipient Combo 3

    Drug: Ibuprofen-LDH

  • Experimental
    Part B Ibuprofen LDH Excipient Combo 5

    Drug: Ibuprofen-LDH

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    Time frame: 12 hours

  2. AUC(0-inf)

    Time frame: 12 hours

07

Study locations

1 site
  • Simbec Orion Ltd
    Merthyr Tydfil, CF48 4DR, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2016, a primary completion of Apr 2017 and a completion of May 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2016
First posted
Nov 28, 2016
Start
Dec 2016
Primary completionActual
Apr 28, 2017
CompletionActual
May 3, 2017
Last update
May 3, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02974361
Lead sponsor
Oxford Pharmascience Ltd
Responsible party
Sponsor
First posted
Nov 28, 2016
Start date
Dec 2016
Primary completion
Apr 28, 2017
Completion
May 3, 2017
Last update
May 3, 2017

Study contacts

Annelize Koch
principal investigator · Simbec Orion Ltd
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion